CompanyGraph
What stands out
- Returns appear driven by leverage
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $3.1B, above the global median of $1.2B
- FinancialsAltman Z-Score 4.13: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Returns appear driven by leverage
Financials view
Market Capitalization
20.76BCNY3.10B · vs all stocks (USD)
Trailing P/E
156.67xRevenue (TTM)
1.11BCNY164.92M · vs all stocks (USD)
Profit Margin
11.56%Beta
0.7180xvs all stocks
52-Week Change
-1.34%vs all stocks
Market Capitalization
20.76BCNY3.10B · vs all stocks (USD)
Enterprise Value
22.54BCNY3.36B · vs all stocks (USD)
Trailing P/E
156.67xForward P/E
78.33xPrice to Sales (TTM)
18.78xPrice to Book (MRQ)
24.40xEnterprise to Revenue
20.39xEnterprise to EBITDA
67.75xGross Margin
61.39%Profit Margin
11.56%Operating Margin
30.24%Return on Assets (TTM)
3.42%Return on Equity (TTM)
15.58%Revenue (TTM)
1.11BCNY164.92M · vs all stocks (USD)
Revenue per Share (TTM)
1.23CNYUpdated Sep 20, 2026Quarterly Revenue Growth
62.50%Gross Profit (TTM)
622.69MCNY92.92M · vs all stocks (USD)
EBITDA (TTM)
440.62MCNY65.75M · vs all stocks (USD)
Net Income (TTM)
127.80MCNY19.07M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
44.00%Operating Cash Flow (TTM)
382.22MCNY57.03M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-121.99MCNY-18.20M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
15.98MCNYFY2025 · Dec 31, 2025Revenue
966.35MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
402.36MCNYFY2025 · Dec 31, 2025Gross Profit
564.00MCNYFY2025 · Dec 31, 2025Operating Income
218.53MCNY32.61M · vs all stocks (USD)
Pre-tax Income
64.23MCNYFY2025 · Dec 31, 2025Income Tax Expense
30.20MCNYFY2025 · Dec 31, 2025Net Income
34.03MCNYFY2025 · Dec 31, 2025EBIT
162.27MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
333.06MCNYFY2025 · Dec 31, 2025Research & Development
126.85MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
117.40MCNYFY2025 · Dec 31, 2025Other Operating Expenses
17.99MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
559.48KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
98.04MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0400CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
914.25MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
914.25MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
34.03MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.54MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
62.17MCNYFY2025 · Dec 31, 2025Free Cash Flow
-171.75MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
77.28MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
34.03MCNYFY2025 · Dec 31, 2025Other Non-cash Items
105.17MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-49.51MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-27.52MCNYFY2025 · Dec 31, 2025Capital Expenditures
-233.92MCNYFY2025 · Dec 31, 2025Net Acquisitions
1.85MCNYFY2025 · Dec 31, 2025Purchase of Investments
-442.85KCNYFY2025 · Dec 31, 2025Sale of Investments
5.84MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-226.67MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.58BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.64BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-94.84MCNYFY2025 · Dec 31, 2025Other Financing Charges
130.57MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-23.96MCNYFY2025 · Dec 31, 2025Shares Outstanding
883.24MSharesUpdated Sep 20, 2026Float Shares
651.67MSharesUpdated Sep 20, 2026% Held by Insiders
25.04%vs all stocks
% Held by Institutions
2.21%vs all stocks
Total Cash (MRQ)
150.79MCNY22.50M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1710CNYUpdated Sep 20, 2026Total Debt (MRQ)
1.92BCNY286.09M · vs all stocks (USD)
Total Debt to Equity (MRQ)
2.22xCurrent Ratio (MRQ)
0.4610xBook Value per Share (MRQ)
0.9630CNYUpdated Sep 20, 2026Total Assets
3.15BCNY470.64M · vs all stocks (USD)
Total Current Assets
523.56MCNYFY2025 · Dec 31, 2025Total Liabilities
2.52BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.63BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
742.32MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.78BCNYFY2025 · Dec 31, 2025Cash
77.11MCNYFY2025 · Dec 31, 2025Cash Equivalents
23.61MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
100.72MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.23MCNYFY2025 · Dec 31, 2025Accounts Receivable
121.55MCNYFY2025 · Dec 31, 2025Inventory
261.38MCNYFY2025 · Dec 31, 2025Accounts Payable
261.97MCNYFY2025 · Dec 31, 2025Short-term Debt
1.28BCNYFY2025 · Dec 31, 2025Other Current Liabilities
14.92MCNYFY2025 · Dec 31, 2025Long-term Debt
623.40MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.32MCNYFY2025 · Dec 31, 2025Common Stock (Book)
883.24MCNYFY2025 · Dec 31, 2025Retained Earnings
-1.81BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
629.93MCNY94.00M · vs all stocks (USD)
52-Week Low
16.23CNYUpdated Sep 20, 202652-Week High
27.70CNYUpdated Sep 20, 202652-Week Change
-1.34%vs all stocks
Beta
0.7180xvs all stocks
50-Day MA
23.10CNYUpdated Sep 20, 2026200-Day MA
21.01CNYUpdated Sep 20, 2026Avg 10-Day Volume
34.89MSharesUpdated Sep 20, 2026Avg 30-Day Volume
44.86MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.1500CNYUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Returns appear driven by leverageSignificant
Return on Equity: 0.16Debt-to-Equity: 2.22
Financial Health
Altman Z-Score 4.13: safe zoneNotable
Altman Z-Score: 4.13
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $3.1B, above the global median of $1.2BNotable
Market cap (USD): 3,097,235,895.711Global Median: 1,201,862,193
Companies that share the same coordination system — how they create, deliver, or capture value.
Harbin Pharmaceutical Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Aodong Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Xiamen Amoytop Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tasly Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Arcus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Regencell Bioscience Holdings Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lepu Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Walvax Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule